Advertisement
Screener

INMUNE BIO INC. (INMB) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate

1.8 / 5 stars · 17/46 Roast Me

INMUNE BIO INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate

INMUNE BIO INC. (INMB) had Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate of 92.00% as of 2024-09-30, per its 10-K filed 2025-03-27.

Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate · last filed 2025-10-30

  • INMUNE BIO INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2023-03-31 was 91.00%.
  • INMUNE BIO INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2023 was 91.00%.
  • INMUNE BIO INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2020 was 94.00%.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility RateShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate as first filedShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 0 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 1 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 3 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 6 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 9 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 12 month
2024-09-3092.00%
10-K · filed 2025-03-27
2024-04-3077.00%
10-Q · filed 2025-10-30
78.00%
10-Q · filed 2024-08-01
2023-12-3191.00%
10-K · filed 2025-03-27
2023-09-3091.00%
10-Q · filed 2023-11-01
2023-06-3091.00%
10-Q · filed 2023-08-07
2023-03-3191.00%
10-Q · filed 2023-05-03
2021-09-30106.00%
10-K · filed 2022-03-03
2021-06-10103.00%
10-Q · filed 2021-08-04
2020-12-3194.00%
10-K · filed 2021-03-04
2020-07-31111.67%
10-K · filed 2022-03-03

Similar stocks

Stock NameCountryMarket CapPE Ratio
ImageneBio, Inc. (IMA)United States$0.056B-1.31
BioAtla, Inc. (BCAB)United States$0.058B-0.21
EXOZYMES INC. (EXOZ)United States$0.058B
Tevogen Inc. (TVGN)United States$0.049B
MiNK Therapeutics, Inc. (INKT)United States$0.063B-5.37
Instil Bio, Inc. (TIL)United States$0.048B-1.73
LeonaBio, Inc. (LONA)United States$0.047B-0.61
Eloxx Pharmaceuticals, Inc. (ELOX)United States$0.065B
Metagenomi Therapeutics, Inc. (MGX)United States$0.044B-0.48
BioStem Technologies, Inc. (BSEM)United States$0.069B